Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TNQTB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
DXC1002
|
|||||
| Synonyms |
DXC1002
Click to Show/Hide
|
|||||
| Organization |
Hangzhou DAC Biotechnology (DAC Biotech) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Anti-TROP2 antibody
|
Antibody Info | ||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
CPT113
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
CrossConju linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The indication landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
2027 Update
ADC-specific functional property
Circulating Stability
| Incubation Time | 7days | Release | <10% | Reference |
[1]
|
|---|---|---|---|---|---|
| Incubation Medium | plasma of five species | ||||
| Description |
In plasma stability studies, wherein DXC1002 was incubated in the plasma of five different species for 168 hours (7 days) at 37 °C, over 90% ADC was intact, exhibiting good stability of the CrossConju™ linker.
Click to Show/Hide
|
||||
2027 Update
General Information of The ADMET Data Related to This ADC
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Elimination Half-Life (t1/2) | 61.27 | h |
The pharmacokinetic behaviors of DXC1002 tested in monkey.
|
[1] |
| Elimination Half-Life (t1/2) | 236.77 | h |
The pharmacokinetic behaviors of DXC1002 tested in rat.
|
[1] |
| Clearance (CL) | 0.41-0.67 | mL/h/kg |
The pharmacokinetic behaviors of DXC1002 tested in monkey.
|
[1] |
| Clearance (CL) | 0.279-0.309 | mL/h/kg |
The pharmacokinetic behaviors of DXC1002 tested in rat.
|
[1] |
References